$Quince Therapeutics (QNCX.US)$
Enrolled 46 participants to date in the company’s Phase 3 NEAT clinical trial to evaluate the neurological effects of EryDex in patients with A-T, including 40 participants in the six to nine year-old primary analysis population. Quince plans to enroll approximately 86 patients with A-T ages six to nine years old (primary analysis population) and app...

$Quince Therapeutics (QNCX.US)$
Quince Therapeutics Receives Notice of Allowance Covering Innovative Method of Use for Lead Indication Ataxia-Telangiectasia
Allowance to extend into 2036 patent claims related to method of treating patients with A-T using the company’s proprietary EryDex process
February 04, 2025 04:05 PM Eastern Standard Time
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the po...

$Quince Therapeutics (QNCX.US)$
Quince's EryDex Shows Strong Safety Profile in Pediatric Ataxia-Telangiectasia Treatment

$Quince Therapeutics (QNCX.US)$ Quince Therapeutics Announces Publication Of 24-Month Safety Data For EryDex In Treating Ataxia-Telangiectasia, Highlighting Reduced Adverse Events Compared To Corticosteroids; Over 6K Monthly Doses Administered To Nearly 400 Patients In Ongoing Phase 3 Study
Quince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, announced the online publicatio...

$Quince Therapeutics (QNCX.US)$
Quince Therapeutics Announces Frontiers in Neurology Publication of Long-Term Safety of EryDex in Pediatric Patients with Ataxia-Telangiectasia
Monday, 27th January at 8:00 am
Quince Therapeutics, Inc. (NASDAQ: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, announced the online publication of safety data from patients with Ataxia-Telangiectasia (A-T) treated with EryDex f...

$Quince Therapeutics (QNCX.US)$ slowly🥳

$Quince Therapeutics (QNCX.US)$ has some insanely target prices 😂. next year some time?

$Quince Therapeutics (QNCX.US)$
No reverse split! Moving up🙏🏻lookinh forward to next week!